A pilot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine

被引:2
|
作者
Kuroda A. [1 ]
Tsuruo M. [2 ]
Aki N. [3 ]
Kondo T. [4 ]
Oguro Y. [5 ]
Tamaki M. [1 ]
Aihara K.-I. [4 ]
Endo I. [4 ]
Matsumoto T. [4 ,6 ]
Abe M. [4 ]
Matsuhisa M. [1 ]
机构
[1] Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15, Kuramoto-cho, Tokushima
[2] Terasawa Hospital, Tokushima
[3] Department of Internal Medicine, Anan Kyoei Hospital, Anan
[4] Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima
[5] Department of Internal Medicine, Takamatsu Municipal Hospital, Kagawa
[6] Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima
关键词
Continuous glucose monitoring (CGM); Insulin degludec; Insulin glargine; Type; 1; diabetes;
D O I
10.1007/s13340-016-0289-4
中图分类号
学科分类号
摘要
Aims: To compare the diurnal glycemic profiles obtained with basal insulin degludec (InsDeg) and basal insulin glargine (InsGla) in patients with type 1 diabetes using continuous glucose monitoring (CGM) in an outpatient setting. Methods: Twenty Japanese patients with type 1 diabetes who were using once-daily InsGla before supper as part of their multiple daily insulin injections were consecutively recruited. CGM was initiated before supper on day 1, and InsGla was switched to InsDeg at the same dose on day 3. The average CGM glucose profile obtained on days 1 and 2 was compared with the corresponding profile for days 5 and 6. The bolus insulin regimen was not changed during the study period. Results: CGM glucose was significantly higher (p < 0.05) from 19:30 to 22:30 and significantly lower (p < 0.05) from 6:30 to 8:00 with basal InsDeg than with basal InsGla. The duration of hypoglycemia (<70 mg/dl) was the same regardless of whether basal InsDeg or basal InsGla was used. Conclusions: The peak in the action profile of InsDeg lasts longer and is possibly stronger than that of InsGla. © 2016, The Japan Diabetes Society.
引用
收藏
页码:112 / 115
页数:3
相关论文
共 50 条
  • [1] Comparison of Insulin Glargine with Insulin Degludec in Type 1 Diabetes Patients
    Kuroda, Akio
    Tsuruo, Miho
    Takeshi, Kondo
    Aki, Nanako
    Oguro, Yukari
    Endo, Itsuro
    Aihara, Ken-ichi
    Tamaki, Motoyuki
    Matsumoto, Toshio
    Matsuhisa, Munehide
    [J]. DIABETES, 2014, 63 : A232 - A232
  • [2] Insulin Degludec Provides Similar Glycemic Control with Insulin Glargine in Patients with Type 2 Diabetes
    Yamada, Satoru
    Komuro, Manaho
    Inoue, Gaku
    Tabata, Mitsuhisa
    Matsubara, Hajime
    Irie, Junichiro
    [J]. DIABETES, 2016, 65 : A250 - A251
  • [3] Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100
    Bevier, Wendy C.
    Castorino, Kristin N.
    Axelrod, Ceara
    Haroush, Gal
    Farfan, Christian C.
    Shelton, Nina
    Nelson, Kristen
    Spink, Lisa A.
    Liu, Hanqing
    Kerr, David
    [J]. DIABETES CARE, 2022, 45 (01) : 67 - 73
  • [4] Similar glycemic profiles with dinner or bedtime insulin glargine in type 1 diabetes
    Vialettes, B
    Grimaldi, A
    Brun, JM
    Halimi, S
    Vaur, L
    Dubroca, I
    Blayo, A
    [J]. DIABETES, 2004, 53 : A150 - A150
  • [5] Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
    Kusunoki, Yoshiki
    Katsuno, Tomoyuki
    Miyakoshi, Kana
    Ikawa, Takashi
    Nakae, Rie
    Ochi, Fumihiro
    Tokuda, Masaru
    Akagami, Takafumi
    Murai, Kazuki
    Miuchi, Masayuki
    Hamaguchi, Tomoya
    Miyagawa, Jun-ichiro
    Namba, Mitsuyoshi
    [J]. DIABETES THERAPY, 2013, 4 (02) : 461 - 472
  • [6] Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
    Yoshiki Kusunoki
    Tomoyuki Katsuno
    Kana Miyakoshi
    Takashi Ikawa
    Rie Nakae
    Fumihiro Ochi
    Masaru Tokuda
    Takafumi Akagami
    Kazuki Murai
    Masayuki Miuchi
    Tomoya Hamaguchi
    Jun-ichiro Miyagawa
    Mitsuyoshi Namba
    [J]. Diabetes Therapy, 2013, 4 : 461 - 472
  • [7] Comparison of Insulin Detemir and Insulin Glargine on Glycemic Variability in Patients with Type 1 and Type 2 Diabetes
    Tone, A.
    Iseda, I.
    Higuchi, C.
    Tsukamoto, K.
    Katayama, A.
    Matsushita, Y.
    Hida, K.
    Wada, J.
    Shikata, K.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2010, 118 (05) : 320 - 324
  • [8] Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study
    Onda, Yoshiko
    Nishimura, Rimei
    Ando, Kiyotaka
    Takahashi, Hiroshi
    Tsujino, Daisuke
    Utsunomiya, Kazunori
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : 149 - 155
  • [9] Efficacy of Switching from Insulin Glargine to Insulin Degludec in Patients with Type 1 Diabetes: A 52-Week Retrospective Study
    Suzuki, Jun
    Yamakawa, Tadashi
    Nagakura, Joe
    [J]. DIABETES, 2015, 64 : A269 - A269
  • [10] A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec among patients with type 1 diabetes
    Yamada K.
    Nakayama H.
    Sato S.
    Tajiri Y.
    Kaku H.
    Tokubuchi I.
    Kato T.
    Soejima E.
    Ohki T.
    [J]. Diabetology International, 2014, 5 (1) : 74 - 77